23 Mar 2017 Targovax ASA's shares have been accepted to list on Oslo Børs, the main Oslo Stock Exchange. Targovax Renate Birkeli, Investor Relations

Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 About Targovax Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock

The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials. An online presentation by Targovax's management to investors, Kim Sutton Golodetz - LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777. An online presentation by Targovax's management to investors, analysts and the press will take place at 10:00 CET today Kim Sutton Golodetz - LHA Investor Relations (US) Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight The quarterly report and presentation are also available at the website www.targovax.com. For further information, please contact: Renate Birkeli , Investor Relations Contact Email info@targovax.com Phone Number 47 21 39 88 10 Targovax AS develops active immunotherapy in the form of cancer vaccines. The lead candidate TG01 is currently in a phase I/II clinical trial in resectable pancreatic cancer.

Targovax investor relations

Anne-Kirsti He brings a wealth of financial and industry experience, which will be instrumental in progressing Targovax’s investor relations and strategy,” said Øystein Soug, CEO of Targovax. “At the same time, Erik Digman Wiklund moves from being CFO to become Chief Business Officer, with responsibility for all our business development activities." Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments. Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no . About Targovax. Activating the patient's immune system to fight cancer OSLO, Norway, Oct. 28, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). The SAB consists of a group of world-renowned experts in immuno-oncology research and drug development carefully selected to act as advisors to Targovax.

Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no . About Targovax. Activating the patient's immune system to fight cancer

The subscription price was at NOK 7, and 10,5m new shares are about to be issu On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual Investor relations. The ironSource story. ironSource is a leading business platform that enables mobile content creators to prosper within the app economy.

Han var tidigare medicinsk chef för Targovax (tidigare Oncos Therapeutics), och engagerad i universitetsbaserad tekniköverföring, samt Investment Manager

Email: renate.birkeli@targovax.com Media and IR enquires: Jan Petter Stiff – Crux Advisers (Norway) Phone: +47 995 13 891. Email: stiff@crux.no Julia Phillips/Simon Conway – FTI Consulting (International) Phone: +44 20 3727 1000. Email: Targovax@fticonsulting.com About Targovax 06.March 2017 at 07:00:00 CET Oslo, Norway, 6 March 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant solid tumors, announces that members of its senior management will present at the following life sciences and investor conferences: 10th European Life Science OSLO, Norway, Feb. 14, 2019 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to targ 23 Feb 2021 Oslo, Norway, 23 February 2021 - Targovax ASA (OSE: TRVX), a clinical stage Kim Sutton Golodetz - LHA Investor Relations (US) Activating the patient's immune system to fight cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to Oslo, 10 December 2020 - Targovax ASA, announces that Øystein Soug, CEO of Targovax, will present the Kim Sutton Golodetz - LHA Investor Relations (US) Oslo, Norway 15 February 2021 – Targovax ASA (OSE: TRVX), a clinical stage immune-oncology Kim Sutton Golodetz – LHA Investor Relations (US) 3 days ago TRVX | Complete Targovax ASA stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. 8 mar 2021 Oslo, 8 March 2021 - Targovax ASA, today announces that members of its executive Kim Sutton Golodetz - LHA Investor Relations (US) Mr. Tuv is currently Investment Director at early stage life science investment company Radforsk with a Non-executive Director of Nextera and member of the Nomination Committee of Targovax ASA. Investor relations: ir@zelluna. com Oslo Area, Norway. Fund raising, Investor Relations, Accounting, Controlling, PR, Legal, HR, IT - launched Xofigo in the US. Orkla Foods Russia (Sladco) grafisk 1 Mar 2021 Resolutions to increase the share capital in Targovax ASA. The Company's IR enquires: Kim Sutton Golodetz - LHA Investor Relations (US) is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.

Email: renate.birkeli@ targovax.com.
Vilka uppgifter har ett skyddsombudet

23, 2021 /PRNewswire/ — Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company Mosa Meat completes $85m Series B investment round. Fokus ligger på att erbjuda en investeringsportfölj innehållande en bred bas av marknader. Sajt: http://www.traction.se/sv/investor-relations/ VD: Petter Stillström Julie Silber anlitas som ny CFO samt ansvarig för Investor Relation Bolaget Han var tidigare medicinsk chef för Targovax (tidigare Oncos Therapeutics), och Näytä lisää. 9 helmikuu 2015 Tykkää (2). Ingwaz.

Normally this period occurs from the fifth banking day of the new quarter and until the interim report has been published. Investor Relations. Here you will find Klarna’s latest and previous interim reports, annual reports and presentations. You will also find information about our debt instruments, as well as relevant contact persons.
Upplevelsebaserat larande

THU, SEP 27, 2018 07:00 CET One of the first six patients showed a complete response to the treatment Oslo, Norway, 27 September 2018 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, today announces interim tumor response data from the first six patients treated with ONCOS-102 followed by the checkpoint inhibitor (CPI) pembrolizumab (KEYTRUDA®) in patients with advanced melanoma whose disease has progressed

2021-03-09 · Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com. Media enquires: Andreas Tinglum – Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no. IR enquires: Kim Sutton Golodetz – LHA Investor Relations (US) Email: kgolodetz@lhai.com Phone: +1 212-838-3777 . About Targovax Investment summary. In the space of a week, Targovax has reported the results from both its lead trials with ONCOS-102, an oncolytic virus. Data from the Phase I trial showed that 35% of anti-PD1 refractory patients with advanced, unresectable melanoma responded to ONCOS-102 plus Keytruda treatment. These data are Targovax’s most significant Oslo, Norway, 5 November 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2020 results.

Investor relations . Teqnion AB är en industrikoncern som verkar inom tre affärsområden: Industry, Growth och Niche. Genom dessa erbjuder Teqnion ledande produkter och specialistkompetens inom utvalda marknadsnischer. Teqnion grundades 2006 och noterades i …

Renate Birkeli, Investor Relations Phone: +47 922 61 624 Email: renate.birkeli@targovax.com Media and IR enquires: Andreas Tinglum - Corporate Communications (Norway) Phone: +47 9300 1773 Email: andreas.tinglum@corpcom.no . About Targovax. Activating the patient's immune system to fight cancer OSLO, Norway, Oct. 28, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). The SAB consists of a group of world-renowned experts in immuno-oncology research and drug development carefully selected to act as advisors to Targovax. SMA (Simple Moving Average), eller Glidande Medelvärde, visar det genomsnittliga värdet historiskt för det intervall du väljer.

Access everything you need as a current or potential shareholder, from share price information and results to recent news and announcements. Learn more. Announcements. Announcements. Regulatory news and announcemnets. Learn more.